Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board -- Ignore unavailable to you. Want to Upgrade?

To: Dave@SI who wrote (1541)	3/31/2016 9:09:42 PM
From: ogi	Read Replies (1) \| Respond to of 1728

The warrant terms now requires a .35 strike, so doubt BCT has had much cash inflow from warrants and Sedar shows Nada as of yesterday. Maybe a few on the spike but doubt significant numbers. Small study or not the first phase trials are impressive and should attract some money for a PP or for that matter a funding partnership of some sort. Were I a major Pharma, I would lever a position for BCT's vaccine at this stage, a few million R&D dollars could beget a substantial position in a promising vaccine for a major.

To: Dave@SI who wrote (1541)	3/31/2016 11:36:36 PM
From: PoorOpinion	Respond to of 1728

Dave, IDK, but another thing to consider is a pre-screen testing is potentially a major change to the approved trial protocol. Imagine you are a desperate cancer patient and you agree to the pre-screen only to be told your genetics suggest treatment is going to be ineffective, that's not a trivial piece of info to pass on to somebody. I'm not saying it shouldnt be done just that it seems like a well thought thru protocol would be needed and (I'm unsure) but sounds like something that would need to be re-submitted to the FDA and passed by hospital ethical boards. Maybe the benefits you mention are worth a re-submission, maybe the approved submission already has the scope to include pre-screening, IDK. Thanks for highlighting the possible alternative sources of financing the trial.